A case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy after primary treatment of triple-negative breast cancer
<p>Abstract</p> <p>We report a case of HER-2-positive recurrent breast cancer showing a clinically complete response to trastuzumab-containing chemotherapy 6 years after primary treatment of triple-negative breast cancer. The primary tumor was negative for HER-2 as determined by im...
Main Authors: | Haruta Rumi, Masumoto Norio, Emi Akiko, Sasada Tatsunari, Kajitani Keiko, Kobayashi Yoshie, Kadoya Takayuki, Shigematsu Hideo, Kataoka Tsuyoshi, Oda Miyo, Arihiro Kouji, Okada Morihito |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-11-01
|
Series: | World Journal of Surgical Oncology |
Subjects: | |
Online Access: | http://www.wjso.com/content/9/1/146 |
Similar Items
-
Risks of trastuzumab‐related cardiotoxicity in breast cancer patients in Taiwan
by: Wei‐Ting Chang, et al.
Published: (2021-12-01) -
Antioxidant Protection against Trastuzumab Cardiotoxicity in Breast Cancer Therapy
by: Gabriel Méndez-Valdés, et al.
Published: (2023-02-01) -
Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer
by: Rea Levicki, et al.
Published: (2023-02-01) -
Dual-phase FDG PET/CT for predicting prognosis in operable breast cancer
by: Haruka Ikejiri, et al.
Published: (2022-10-01) -
Lipid Metabolism Reprogramming and Trastuzumab Resistance in Breast Cancer Cell Lines Overexpressing the ERBB2 Membrane Receptor
by: Katia Cortese, et al.
Published: (2023-05-01)